Navigation Links
A closer look at PARP-1 reveals potential new drug targets
Date:5/11/2012

PHILADELPHIAA new study published in Science May 11 is shedding light on the molecular details of PARP-1, a DNA damage-detecting enzyme that when inhibited has been shown to be effective in fighting cancer and other diseases.

The investigation led by John M. Pascal, Ph.D., an assistant professor in the Department of Biochemistry and Molecular Biology at Thomas Jefferson University and Jefferson's Kimmel Cancer Center, revealed new target sitesincluding specialized "zinc finger" domainsfor drugs aiming to stop PARP-1 activity.

The idea for this area of research is to identify more specific PARP-1 inhibitors that achieve a targeted inhibition, with less potential for side effects. Drugs inhibiting PARP-1 have also been proven effective in treating inflammation and cardiac disease.

"PARP-1 has been identified as a valuable target, but what's special about it? What really are its weak points in the way it gets activated?" said Dr. Pascal. "We wanted to define a structural and mechanistic framework to better understand how to specifically inhibit PARP-1."

The weak points were found to be multi-domain interfaces that are uniquely found in PARP-1. What researchers now know is that multiple domains of PARP-1 come together and bind to DNA damage, and this "communication" between domains is essential for DNA damage-dependent PARP-1 activity.

PARP-1 is a protein that detects and responds to breaks in the structure of DNA, a potentially lethal form of damage to our genetic information. If PARP-1 activity is impaired, DNA strand breaks are not repaired and instead are converted into more dangerous types of DNA damage. In normal tissue, a repair mechanism called homologous recombination picks up the slack and fixes the damaged DNA. However, in cancers that carry the BRCA mutation, like certain breast and ovarian cancers, homologous recombination is inactivated. Therefore, the cancerous cells have become dependent on the role PARP-1 plays in DNA repair.

In a more general scenario, inhibiting PARP‑1 has been successful when combined with DNA‑damaging drugs because it enhances the apoptotic activity of these drugs. In other words, it helps halt tumor growth.

Today, many PARP-1 inhibitors being tested in preclinical and clinical studies target the catalytic active site. But this approach is limiting because the catalytic site is similar to those found in other PARP-like proteins that carry out other essential cellular functions, thus increasing the potential for off target side effects.

"What was exciting in our structure of PARP-1 is that there are specialized sites on the protein that can be inhibited; you can effectively kill catalytic activity without having to touch the catalytic active site," said Dr. Pascal.

Using X-ray crystallography, researchers studied the interaction amongst the component domains of PARP-1 and their combined role in binding to DNA damage. The PARP-1/DNA structure revealed a network of interdomain contacts formed upon DNA binding. These domains have to come together and assemble, the researchers found, to have catalytic activity.

"Our work indicates that we should be looking for inhibitors that prevent these domains from coming together," Dr. Pascal said. "Rather than screen for inhibitors with catalytic activity as a readout, we can screen for inhibitors that disrupt the communication between the PARP-1 domains, which would in turn shut down catalytic activity."

Closer attention to these specialized domains could inspire the design of a new class of PARP inhibitors.

"Dr. Pascal's structural and biochemical characterization reveals how recognition of DNA damage and communication between domains control the activity of PARP‑1," said Barbara Gerratana, Ph.D., who oversees enzyme catalysis grants at the National Institutes of Health's National Institute of General Medical Sciences, which partially supported the study. "This work is a major breakthrough in understanding an enzyme essential for regulation of cell proliferation and a promising target for cancer therapeutics."


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert  

Related medicine news :

1. Research Gets Closer to Genetic Roots of Glaucoma
2. Scientists May Be Closer to Developing Red Wine Drug
3. Handheld device for doing blood tests moves closer to medical use
4. Cheaper DNA Sequencing Coming Closer
5. Researchers Closer to Developing Universal Meningitis B Vaccine
6. Gold nanoparticles bring scientists closer to a treatment for cancer
7. Scientists Appear One Step Closer to Reading Minds
8. Researchers move closer to identifying new class of asthma, COPD drugs
9. Grant funds next phase in bringing healthier sorghum closer to underserved communities
10. New weight loss discovery by Harvard scientists moves us closer to the Pill for obesity
11. Noninvasive test for trisomy 21 closer at hand
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A closer look at PARP-1 reveals potential new drug targets
(Date:12/8/2016)... ... 08, 2016 , ... The West Virginia Medical Institute (WVMI) ... The name change aligns the entire company with its existing Quality Insights branded ... “We are very proud of the achievements associated with the West Virginia Medical ...
(Date:12/8/2016)... ... 2016 , ... Russ DiGilio , founder and owner ... campaign which supported local breast cancer organizations during National Breast Cancer Awareness Month ... initiative, and we’re very pleased with the participation in every franchisee’s community,” ...
(Date:12/8/2016)... ... 2016 , ... Mirixa Corporation , a leading healthcare ... patient care services, has announced the promotions of Karen Litsinger to senior vice ... sales. , Litsinger joined Mirixa in 2008 after serving as a partner ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
Breaking Medicine Technology: